In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

I’m wondering if any studies explain this and what’s the best way to address it. Should I increase the dose further or switch ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

Lenacapavir for Alzheimer’s, an orca attacking a shark, and a moon landing are set to mark key scientific and technological ...

The Houthis, an Iranian-backed group based in Yemen, have launched repeated attacks despite the Israeli military’s retaliatory airstrikes. By Adam Rasgon Stepped up attacks by Russia are ...

New York Judge Delays Start of Trial Between CFTC and Gemini Trust Company ...